[go: up one dir, main page]

NO20082135L - HIV integrase inhibitorer - Google Patents

HIV integrase inhibitorer

Info

Publication number
NO20082135L
NO20082135L NO20082135A NO20082135A NO20082135L NO 20082135 L NO20082135 L NO 20082135L NO 20082135 A NO20082135 A NO 20082135A NO 20082135 A NO20082135 A NO 20082135A NO 20082135 L NO20082135 L NO 20082135L
Authority
NO
Norway
Prior art keywords
hiv integrase
hiv
integrase inhibitors
compounds
aids
Prior art date
Application number
NO20082135A
Other languages
English (en)
Inventor
B Narasimhulu Naidu
Margaret E Sorenson
Yasutsugu Ueda
Michael A Walker
John D Matiskella
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20082135L publication Critical patent/NO20082135L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Oppfinnelsen omfatter en serie bicykliske pyrimidinonforbindelser med formel I som hemmer HIV integrase og forhindrer viral integrering i humant DNA. Denne virkningen gjør forbindelsene anvendelige for behandling av HIV infeksjon og AIDS. Oppfinnelsen omfatter også farmasøytiske preparater og metoder for behandling av de infisert med HIV.
NO20082135A 2005-11-16 2008-05-07 HIV integrase inhibitorer NO20082135L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73706205P 2005-11-16 2005-11-16
PCT/US2006/044378 WO2007059229A1 (en) 2005-11-16 2006-11-15 Hiv integrase inhibitors

Publications (1)

Publication Number Publication Date
NO20082135L true NO20082135L (no) 2008-08-13

Family

ID=37844943

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082135A NO20082135L (no) 2005-11-16 2008-05-07 HIV integrase inhibitorer

Country Status (8)

Country Link
US (1) US7902182B2 (no)
EP (1) EP1948621A1 (no)
JP (1) JP2009515985A (no)
KR (1) KR20080072718A (no)
CN (1) CN101351452A (no)
AU (1) AU2006315446A1 (no)
NO (1) NO20082135L (no)
WO (1) WO2007059229A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763630B2 (en) * 2007-06-06 2010-07-27 Bristol-Myers Squibb Company HIV integrase inhibitors
GB0804067D0 (en) * 2008-03-04 2008-04-09 Syngenta Participations Ag Chemical compounds
WO2010042392A2 (en) * 2008-10-06 2010-04-15 Merck & Co., Inc. Hiv integrase inhibitors
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US8383639B2 (en) * 2009-10-15 2013-02-26 Bristol-Myers Squibb Company HIV integrase inhibitors
US8283366B2 (en) 2010-01-22 2012-10-09 Ambrilia Biopharma, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
CN102336751A (zh) * 2010-07-16 2012-02-01 爱维艾珂瑟有限公司 新型抗病毒剂
MX2014006479A (es) 2011-11-30 2015-01-22 Univ Emory Inhibidores antivirales de la janus cinasa utiles en el tratamiento o prevencion de infecciones retrovirales y otras infecciones virales.
CN102911124B (zh) * 2012-10-25 2015-11-25 山东大学 羟基嘧啶酮类化合物及其制备方法与应用
EP2931730B1 (en) 2012-12-17 2019-08-07 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
US9493479B2 (en) 2013-04-16 2016-11-15 Merck Sharp & Dohme Corp. Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
PT2997033T (pt) 2013-05-17 2018-01-25 Merck Sharp & Dohme Compostos heterocíclicos tricíclicos fundidos como inibidores de vih integrase
US9951079B2 (en) 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
US9861620B2 (en) 2013-09-27 2018-01-09 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as HIV integrase inhibitors
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
EP3377066B1 (en) 2015-11-17 2021-04-07 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
EP3389380B1 (en) 2015-12-15 2021-07-21 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
CN112088005A (zh) * 2018-04-27 2020-12-15 默沙东公司 可用作hiv整合酶抑制剂的三环杂环化合物
WO2022098700A1 (en) * 2020-11-03 2022-05-12 Cassava Sciences, Inc. Inhibiting an immune response mediated by one or more of tlr2, rage, ccr5, cxcr4 and cd4

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60124577T2 (de) * 2000-10-12 2007-09-27 Merck & Co., Inc. Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
JP4733986B2 (ja) 2002-12-27 2011-07-27 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ＨＩＶインテグラーゼ阻害薬として有用なテトラヒドロ−４Ｈ−ピリド［１，２−ａ］ピリミジン類および関連する化合物
AR046938A1 (es) 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
US7176196B2 (en) * 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
EP1866313A1 (en) 2005-03-31 2007-12-19 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Hiv integrase inhibitors
AU2006244424B2 (en) 2005-05-10 2011-09-22 Merck Sharp & Dohme Corp. HIV integrase inhibitors

Also Published As

Publication number Publication date
US7902182B2 (en) 2011-03-08
CN101351452A (zh) 2009-01-21
JP2009515985A (ja) 2009-04-16
KR20080072718A (ko) 2008-08-06
EP1948621A1 (en) 2008-07-30
AU2006315446A1 (en) 2007-05-24
WO2007059229A1 (en) 2007-05-24
US20070111985A1 (en) 2007-05-17

Similar Documents

Publication Publication Date Title
NO20082135L (no) HIV integrase inhibitorer
NO20065879L (no) Bisykliske heterosykler som HIV-integraseinhibitorer
NO20081935L (no) HIV-integraseinhibitorer
WO2008002959A3 (en) Hiv integrase inhibitors
NO20080797L (no) Bicykliske heterocykler som HIV Integrase inhibitorer
NO20065443L (no) HIV-Integraseinhibitorer: Sykliske pyrimidinonforbindelser
CY1126771T1 (el) Συνδυασμοι δολουτεγραβιρης και λαμιβουδινης για την αγωγη λοιμωξης απο hiv
MX2010009995A (es) Heterociclos puenteados como inhibidores de la integrasa del virus de inmunodeficiencia humana.
NO20090202L (no) Prolylhydroksylaseinhibitorer
WO2004096128A3 (en) Hiv integrase inhibitors
WO2007059125A3 (en) Hiv integrase inhibitors
WO2005115398A3 (en) Hiv integrase inhibitors
NO20063479L (no) Fosfonater, monofosfonamidater og bis-fosfonamidater for behandling av virussykdommer
NO20083585L (no) Hetero-bisykliske antivirale forbindelser
ATE473975T1 (de) Chemische verbindungen
ATE398613T1 (de) Chemische verbindungen
ATE502038T1 (de) Azyklische amininhibitoren von nukleosidphosphorylasen und hydrolasen
TW200635918A (en) Pharmaceutical compounds
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20070656L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
NO20063958L (no) HIV integrase inhibitorer
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
BRPI0513405A (pt) tienopirimidinas úteis como inibidores de aurora quinase
EA201170344A1 (ru) Азаиндольные ингибиторы iap